Search research articles
Contact Us
Filters
Showing results (81-90 of 296) with videos related to
Page
of 30
Sort By:
Human Immunology
|
April 17, 2012
Evaluation of a non-viral vaccine in smallpox-vaccinated individuals and immunized HLA-transgenic mice
Alice P Taylor, Boby Makabi-Panzu, Xiaochuan Chen, et al.
Blood
|
August 28, 2009
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas
Edmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Plos One
|
May 23, 2013
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells
Donglin Liu, Chien-Hsing Chang, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2008
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)
M Jules Mattes, Robert M Sharkey, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2007
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma
David V Gold, Zarir Karanjawala, David E Modrak, et al.
Journal of Labelled Compounds & Radiopharmaceuticals
|
January 11, 2014
Al(18) F labeling of peptides and proteins
Peter Laverman, William J McBride, Robert M Sharkey, et al.
Seminars in Nuclear Medicine
|
March 31, 2010
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy
Robert M Sharkey, Edmund A Rossi, William J McBride, et al.
EJNMMI Research
|
December 13, 2019
Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models
Fortuné M K Elekonawo, Desirée L Bos, David M Goldenberg, et al.
Molecular Cancer Therapeutics
|
May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Chien-Hsing Chang, Yang Wang, Maria Zalath, et al.
Oncotarget
|
June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Page
of 30
Search research articles
Search
Showing results (81-90 of 296) with videos related to
Sort By:
Page
of 30
Human Immunology
|
April 17, 2012
Evaluation of a non-viral vaccine in smallpox-vaccinated individuals and immunized HLA-transgenic mice
Alice P Taylor, Boby Makabi-Panzu, Xiaochuan Chen, et al.
Blood
|
August 28, 2009
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas
Edmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Plos One
|
May 23, 2013
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells
Donglin Liu, Chien-Hsing Chang, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2008
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)
M Jules Mattes, Robert M Sharkey, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2007
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma
David V Gold, Zarir Karanjawala, David E Modrak, et al.
Journal of Labelled Compounds & Radiopharmaceuticals
|
January 11, 2014
Al(18) F labeling of peptides and proteins
Peter Laverman, William J McBride, Robert M Sharkey, et al.
Seminars in Nuclear Medicine
|
March 31, 2010
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy
Robert M Sharkey, Edmund A Rossi, William J McBride, et al.
EJNMMI Research
|
December 13, 2019
Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models
Fortuné M K Elekonawo, Desirée L Bos, David M Goldenberg, et al.
Molecular Cancer Therapeutics
|
May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Chien-Hsing Chang, Yang Wang, Maria Zalath, et al.
Oncotarget
|
June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Page
of 30